AR and hepatocellular carcinoma: In agreement with a recent report, three of 22 patients with breast cancer expressing AR and treated with abiraterone experienced disease stabilization that lasted longer than 6 months.13 One patient with hepatocellular carcinoma, one with bladder carcinoma, and one with ependymoma treated with abiraterone in SHIVA01 experienced disease stabilization that lasted longer than 6 months; however, no evidence of efficacy of antiandrogens in these cancer types has been reported in the literature.14-17